

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000180

International filing date: 19 January 2005 (19.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0401269.6
Filing date: 21 January 2004 (21.01.2004)

Date of receipt at the International Bureau: 02 March 2005 (02.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



PCT | GB 2005 | 000180



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

AmBrewer

Dated


8 February 2005

21. JAN. 2004 16:02

GLOBAL IP PATENTS

NO. 4832 P. 2

Patents Form 1/77

Patents Act 1977
(Rule 16)21JAN04 EB67103-1 D02934
P01/7700 0.00-0401269.6 ACCOUNT CHA

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference 101365-1

2. Patent application number
(The Patent Office will fill in this part)

21 JAN 2004

0401269.6

3. Full name, address and postcode of the or of
each applicant (underline all surnames)AstraZeneca AB
SE-151 85 Sodertalje
Sweden

Patents ADP number (if you know it)

07882448003

If the applicant is a corporate body, give the
country/state of its incorporation

Sweden

4. Title of the invention

COMPOUNDS

5. Name of your agent (if you have one)

Neil Godfrey Alasdair PHILLIPS

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)AstraZeneca
Global Intellectual Property
P O Box 272
Meraside, Alderley Park
Macclesfield,
Cheshire SK10 4GR

Patents ADP number (if you know it)

08179707001

6. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

01Patent Form 41/77-08

Patents Form 1/77

1. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

25

Claim(s)

6

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

S. A. Douglas

Date 21/01/2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Shirley Douglas - 01625 510057

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

101365

-1-

COMPOUNDS

The present invention relates to certain heterocyclic compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved cysteine motif.

10 At the present time, the chemokine superfamily comprises three groups exhibiting characteristic structural motifs, the C-X-C, C-C and C-X₃-C families. The C-X-C and C-C families have sequence similarity and are distinguished from one another on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues. The C-X₃-C family is distinguished from the other two families on the basis of having a triple amino acid

15 insertion between the NH-proximal pair of cysteine residues.

The C-X-C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).

The C-C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils. Examples include human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).

20 3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1 α and 1 β (MIP-1 α and MIP-1 β).

The C-X₃-C chemokine (also known as fractalkine) is a potent chemoattractant and activator of microglia in the central nervous system (CNS) as well as of monocytes, T cells, NK cells and mast cells.

25 NK cells and mast cells.


Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

30 family) and CX₃CR1 for the C-X₃-C family. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.

101365

-2-

The present invention provides compounds of formula (1), a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof:



5

wherein Y is selected from a bond, -S-, -O-, -NR⁵-, -CF₂-CH₂-, -CF₂CF₂-, -CONR⁵-, phenyl or heteroaryl.

wherein R¹ is a group selected from C₃₋₇carbocyclyl, C₁₋₃alkyl, C₂₋₆alkenyl and C₂₋₆alkynyl;

wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from fluoro, nitrile, -OR⁴, -NR⁵R⁶, -CONR⁵R⁶, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -SO₂R¹⁰, -SO₂NR⁵R⁶, -NR⁸SO₂R⁹, phenyl or heteroaryl; wherein phenyl and heteroaryl are optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, -OR⁴, -NR⁵R⁶, -CONR⁵R⁶, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -SO₂R¹⁰, -SO₂NR⁵R⁶, -NR⁸SO₂R⁹, C₁₋₆alkyl and trifluoromethyl;

15 wherein R² is C₃₋₇carbocyclyl, optionally substituted by 1, 2 or 3 substituents independently selected from:

(a) fluoro, -OR⁴, -NR⁵R⁶, -CONR⁵R⁶, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -SO₂R¹⁰, -SO₂NR⁵R⁶, -NR⁸SO₂R⁹;

(b) a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S, -NR⁸

20 and whereby the ring is optionally substituted by C₁₋₃alkyl or fluoro; or

(c) phenyl or heteroaryl, each of which is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, -OR⁴, -NR⁵R⁶, -CONR⁵R⁶, -NR⁸COR⁹, -SO₂NR⁵R⁶, -NR⁸SO₂R⁹, C₁₋₆alkyl and trifluoromethyl;

or R² is a group selected from C₁₋₃alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl wherein the group is

25 substituted by 1, 2 or 3 substituents independently selected from hydroxy, amino, C₁₋₆alkoxy, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, N-(C₁₋₆alkyl)-N-(phenyl)amino, N-C₁₋₆alkylcarbamoyl, N,N-di(C₁₋₆alkyl)carbamoyl, N-(C₁₋₆alkyl)-N-(phenyl)carbamoyl, carboxy, phenoxycarbonyl, -NR⁸COR⁹, -SO₂R¹⁰, -SO₂NR⁵R⁶ and -NR⁸SO₂R⁹;

101365

-3-

wherein R^3 is hydrogen or independently R^2 ;

R^4 is hydrogen or a group selected from C_{1-6} alkyl and phenyl, wherein the group is optionally substituted by 1 or 2 substituents independently selected from halo, phenyl, $-OR^{11}$ and -

5 $NR^{12}R^{13}$;

R^5 and R^6 are independently hydrogen or a group selected from C_{1-6} alkyl and phenyl wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl, $-OR^{14}$, $-NR^{15}R^{16}$, $-COOR^{14}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2R^{10}$, $-SONR^{15}R^{16}$ and $NR^{15}SO_2R^{16}$

10 or

R^5 and R^6 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally containing a further heteroatom selected from oxygen and nitrogen atoms, which ring is optionally substituted by 1, 2 or 3 substituents independently selected from phenyl, $-OR^{14}$, $-COOR^{14}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$,

15 $-NR^{15}COR^{16}$, $-SO_2R^{10}$, $-SONR^{15}R^{16}$, $NR^{15}SO_2R^{16}$ or C_{1-6} alkyl (optionally substituted by 1 or 2 substituents independently selected from halo, $-NR^{15}R^{16}$ and $-OR^{17}$ groups);

R^{10} is hydrogen or a group selected from C_{1-6} alkyl or phenyl, wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$; and each of R^7 , R^8 , R^9 , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} is independently hydrogen,

20 C_{1-6} alkyl or phenyl;

R^x is trifluoromethyl, $-NR^5R^6$, phenyl, naphthyl, monocyclic or bicyclic heteroaryl wherein a heteroring may be partially or fully saturated and one or more ring carbon atoms may form a carbonyl group, and wherein each phenyl or heteroaryl group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$,
25 $-COR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6} alkyl or trifluoromethyl;;

or R^x is a group selected from C_{3-7} carbocyclyl, C_{1-8} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl whereby the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$,

30 $-NR^8SO_2R^9$, phenyl or heteroaryl; and wherein each phenyl or heteroaryl group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6} alkyl or trifluoromethyl.

101365

-4-

In particular Y is a bond; Y is -S-; Y is -O-; Y is -NR⁵; Y is -CF₂-CH₂-; Y is -CF₂CF₂-; Y is -CONR⁵-; Y is phenyl; or Y is heteroaryl.

Certain compounds of formula (1) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the
5 compounds of formula (1) and mixtures thereof including racemates.

The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

10 Within the present invention it is to be understood that a compound of formula (1) or a salt, solvate or *in vivo* hydrolysable ester thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form and mixtures thereof and is not to be limited merely to any one tautomeric
15 form utilised within the formulae drawings. The formulae drawings within this specification can represent only one of the possible tautomeric forms and it is to be understood that the specification encompasses all possible tautomeric forms of the compounds drawn not just those forms which it has been possible to show graphically herein.

It is also to be understood that certain compounds of formula (1) and salts thereof
20 can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.

The present invention relates to the compounds of formula (1) as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the
25 compounds of formula (1) and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially
30 hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. Suitable salts include hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, malates, fumarates,

101365

-5-

succinates, lactates, tartrates, oxalates, methanesulphonates or *p*-toluenesulphonates. Pharmaceutically acceptable salts of the invention may also include basic addition salts of the compounds of formula (1) as hereinbefore defined which are sufficiently acidic to form such salts. Such salts may be formed with an inorganic or organic base which affords a

5 pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a lithium, sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or an organic amine salt, for example a salt with methylamine, dimethylamine, trimethylamine, triethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine. Other basic addition salts include

10 aluminium, zinc, benzathine, chlorprocaine, choline, diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine or procaine.

The present invention further relates to an *in vivo* hydrolysable ester of a compound of formula (1). An *in vivo* hydrolysable ester of a compound of formula (1) which contains carboxy or hydroxy group is, for example a pharmaceutically acceptable ester which

15 is cleaved in the human or animal body to produce the parent acid or alcohol. Such esters can be identified by administering, for example, intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluid.

Suitable pharmaceutically acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example

20 pivaloyloxymethyl, phthalidyl esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

25 Suitable pharmaceutically-acceptable esters for hydroxy include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the *in vivo* hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of *in-vivo* hydrolysable ester forming

30 groups for hydroxy include C₁₋₁₀alkanoyl, for example acetyl; benzoyl; phenylacetyl; substituted benzoyl and phenylacetyl, C₁₋₁₀alkoxycarbonyl (to give alkyl carbonate esters), for example ethoxycarbonyl; di-(C₁₋₄)alkylcarbamoyl and *N*-(di-(C₁₋₄)alkylaminoethyl)-*N*-(C₁₋₄)alkylcarbamoyl (to give carbamates); di-(C₁₋₄)alkylaminoacetyl and carboxyacetyl.

101365

-6-

Examples of ring substituents on phenylacetyl and benzoyl include aminomethyl, (C₁₋₄)alkylaminomethyl and di-((C₁₋₄)alkyl)aminomethyl, and morpholino or piperazino linked from a ring nitrogen atom via a methylene linking group to the 3- or 4- position of the benzoyl ring. Other interesting in-vivo hydrolysable esters include, for example, R^AC(O)O(C₁₋₆)alkyl-
5 CO-, wherein R^A is for example, benzyloxy-(C₁₋₄)alkyl, or phenyl. Suitable substituents on a phenyl group in such esters include, for example, 4-(C₁₋₄)piperazino-(C₁₋₄)alkyl, piperazino-(C₁₋₄)alkyl and morpholino-(C₁₋₄)alkyl.

In this specification the term "alkyl" includes both straight-chain and branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are
10 specific for the straight chain version only and references to individual branched-chain alkyl groups such as *t*-butyl are specific for the branched chain version only. For example, "C₁₋₃alkyl" includes methyl, ethyl, propyl and isopropyl and examples of "C₁₋₆alkyl" include the examples of "C₁₋₃alkyl" and additionally *t*-butyl, pentyl, 2,3-dimethylpropyl, 3-methylbutyl and hexyl. Examples of "C₁₋₈alkyl" include the examples of "C₁₋₆alkyl" and
15 additionally heptyl, 2,3-dimethylpentyl, 1-propylbutyl and octyl. An analogous convention applies to other terms, for example "C₂₋₆alkenyl" includes vinyl, allyl, 1-propenyl, 2-butenyl, 3-butenyl, 3-methylbut-1-enyl, 1-pentenyl and 4-hexenyl and examples of "C₂₋₆alkynyl" includes ethynyl, 1-propynyl, 3-butyne, 2-pentyne and 1-methylpent-2-ynyl.

"C₃₋₇carbocyclyl" is a saturated, partially saturated or unsaturated, monocyclic ring
20 containing 3 to 7 carbon ring atoms wherein a -CH₂- group can optionally be replaced by a -C(O)-. Suitable examples of "carbocyclyl" are cyclopropyl, cyclopentyl, cyclobutyl, cyclohexyl, cyclohexenyl, 4-oxocyclohex-1-yl and 3-oxocyclohept-5-en-1-yl.

The term "halo" refers to fluoro, chloro, bromo and iodo.

Examples of "C₁₋₆alkoxy" include methoxy, ethoxy, propoxy, isopropoxy,
25 butyloxy, pentyloxy, 1-ethylpropoxy and hexyloxy. Examples of "C₁₋₆alkylamino" include methylamino, ethylamino, propylamino, butylamino and 2-methylpropylamino. Examples of "di(C₁₋₆alkyl)amino" include dimethylamino, *N*-methyl-*N*-ethylamino, diethylamino, *N*-propyl-*N*-3-methylbutylamino. Examples of "*N*-(C₁₋₆alkyl)-*N*-(phenyl)amino" include *N*-methyl-*N*-phenylamino, *N*-propyl-*N*-phenylamino and *N*-(2-methylbutyl)-*N*-phenylamino.
30 Examples of "*N*-(C₁₋₆alkyl)carbamoyl" are *N*-methylcarbamoyl, *N*-ethylcarbamoyl and *N*-(2-ethylbutyl)carbamoyl. Examples of "*N*-(C₁₋₆alkyl)-*N*-(phenyl)carbamoyl" include *N*-methyl-*N*-phenylcarbamoyl, *N*-butyl-*N*-phenylcarbamoyl and *N*-(3-methylpentyl)-*N*-(phenyl)carbamoyl. Examples of "*N,N*-di(C₁₋₆alkyl)carbamoyl" include *N,N*-dimethylcarbamoyl, *N*-methyl-*N*-

101365

-7-

ethylcarbamoyl and *N*-propyl-*N*-(2-methylbutyl)carbamoyl. Examples of "C₁₋₆alkylthio" include methylthio, ethylthio, propylthio, butylthio and 2-methylbutylthio.

"Heteroaryl" is a monocyclic or bicyclic aryl ring containing 5 to 10 ring atoms of which 1, 2, 3 or 4 ring atoms are chosen from nitrogen, sulphur or oxygen. Examples of
 5 heteroaryl include pyrrolyl, furanyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, benzfuranyl, benzthieno, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, benztriazolyl, quinoliny, isoquinoliny and naphthiridinyl. Conveniently heteroaryl is selected from imidazolyl, pyrazolyl, thiazolyl,
 10 isoxazolyl, furanyl, thienyl, isoxazolyl, or indazolyl.

Examples of "a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S and NR⁸" include oxetanyl, azetidiny, benzodiazolyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl and homopiperazinyl. tetrahydrodioxanyl, such as oxetanyl.
 15 azetidiny, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl and homopiperazinyl, further such as pyrrolidinyl, tetrahydropyridinyl, piperidinyl, piperazinyl, and morpholinyl.

Examples of "a 4- to 7-membered saturated heterocyclic ring system" include azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl and morpholinyl.

20 Where optional substituents are chosen from "1, 2 or 3" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups. An analogous convention applies to substituents chosen from "1 or 2" groups.

Particular compounds of the invention include *N*-[4-[(2,3-difluorophenyl)methyl]thio]-6-
 25 [[[1*R*]-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-methanesulfonamide;
N-[4-[[[(2,3-difluorophenyl)methyl]thio]-6-[[1*R*]-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-1-azetidinesulfonamide and pharmaceutically acceptable salts, solvates or *in vivo* hydrolysable esters thereof.


Each of the above mentioned compounds and the pharmaceutically acceptable salt,
 30 solvate or *in vivo* hydrolysable ester thereof, individually is a particular aspect of the invention.

101365

-8-

The present invention further provides a process for the preparation of compounds of formula (1) as defined above which comprises:

(a) treating a compound of formula (2):



5

(2)

wherein Y , R^1 , R^2 and R^3 are as defined in formula (1) with sulfonamides ($\text{R}^3\text{SO}_2\text{NH}_2$) where R^3 is as defined in formula (1).

and optionally thereafter (i), (ii), (iii), (iv), or (v) in any order:

- 10 i) removing any protecting groups;
- ii) converting the compound of formula (1) into a further compound of formula (1)
- iii) forming a salt
- iv) forming a prodrug
- v) forming an *in vivo* hydrolysable ester.

15


Reaction of compounds of formula (2) wherein Y , R^1 , R^2 and R^3 are as defined in formula (1) with sulfonamides ($\text{R}^3\text{SO}_2\text{NH}_2$) can be carried out in the presence of a suitable base, solvent and catalyst. Examples of suitable bases include metal carbonates such as those from caesium, potassium, lithium or sodium. Most preferably Caesium carbonate is used. Suitable solvents include ethers such as tetrahydrofuran, 1,4-dioxane, glyme and diglyme.

- 20 Preferably 1,4-dioxane is used. The temperature of the reaction can be performed between 10°C and 120°C , preferably at 100°C . Examples of suitable catalysts include a suitable palladium(0) source such as palladium tris(dibenzylideneacetone)dipalladium(0) ($\text{Pd}_2(\text{dba})_3$), or tetrakis(triphenylphosphine) ($\text{Pd}(\text{Ph}_3)_4$) (either in 0.01-0.5 mol equivalents) in the presence of a suitable ligand such as (9,9-dimethyl-9H-xanthene-4,5-diyl)bis[diphenyl-phosphine (Xantphos), or 2-dicyclohexyl-phosphino-2'-(N,N-dimethylamino)biphenyl (either in 0.01-0.5 mol equivalents). Preferably the catalyst combination is
- 25 tris(dibenzylideneacetone)dipalladium(0) ($\text{Pd}_2(\text{dba})_3$) with 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos) in 0.01-0.5 mol equivalents in 1,4-dioxane at 100°C with caesium carbonate as the base.

101365

-9-

Compounds of formula (2) wherein Y, R¹, R² and R³ are as defined in formula (1), can be prepared from compounds of formula (3) wherein R¹ are as defined in formula (1) and L is halogen by treatment with nucleophilic amines NR²R³ as defined in formula (1) in the presence of a suitable base and solvent.



(3)

Examples of suitable bases include trialkylamines, such as triethylamine or *N,N*-diisopropylethylamine. Suitable solvents include ethers such as tetrahydrofuran, 1,4-dioxane, glyme and diglyme. The temperature of the reaction can be performed between 0°C and 50°C. Preferably tetrahydrofuran is used at ambient temperature.

Compounds of formula (3) wherein Y is -S- and R¹ is as defined in formula (1) and L is halogen may be prepared by treating cyanuric chloride with a thiol of formula R¹SH wherein R¹ is defined as in formula (1) in presence of a suitable base and solvent.. Suitable solvent include ethers such as tetrahydrofuran, 1,4-dioxane, glyme and diglyme. Suitable bases include trialkylamines, such as triethylamine or *N,N*-diisopropylethylamine. Preferably *N,N*-diisopropylethylamine is used as a base and tetrahydrofuran as the solvent is used at ambient temperature.

Compounds of formula (3) wherein Y is a bond and R¹ is as defined in formula (1) and L is halogen may be prepared by treating cyanuric chloride with a suitable Grignard reagent for example of formula R¹(CH₂)_nMgL wherein L is a halogen and R¹ is defined as in formula (1) in presence of a suitable solvent such tetrahydrofuran or 1,4-dioxane. Preferably tetrahydrofuran at ambient temperature is used.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (1) may involve, at an appropriate stage, the removal of one or more protecting groups. The protection and deprotection of functional groups is fully described in 'Protective Groups in Organic Chemistry', edited by J. W. F. McOmie, Plenum Press (1973), and 'Protective Groups in Organic Synthesis', 2nd edition, T. W. Greene & P. G. M. Wuts, Wiley-Interscience (1991).

101365

-10-

A compound of formula (1) may be prepared from another compound of formula (1) by chemical modification. Examples of chemical modifications include standard alkylation, arylation, heteroarylation, acylation, sulphonylation, phosphorylation, aromatic halogenation and coupling reactions. These reactions may be used to add new substituents or to modify existing substituents. Alternatively, existing substituents in compounds of formula (1) may be modified by, for example, oxidation, reduction, elimination, hydrolysis or other cleavage reactions to yield other compounds of formula (1).

Novel intermediate compounds form a further aspect of the invention.

The compounds of formula (1) above may be converted to a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as discussed above. The salt is preferably a basic addition salt.

The compounds of formula (1) have activity as pharmaceuticals, in particular as modulators of chemokine receptor activity, such as for example CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family; and especially as modulators of CXCR2 activity. Use of the compounds as modulators of each above mentioned receptor represents a separate and independent aspect of the invention.

The compounds of formula (1) may be used in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines. Examples of such conditions/diseases include (each taken independently):

- (1) **the respiratory tract** - obstructive airways diseases including chronic obstructive pulmonary disease (COPD); asthma, such as bronchial, allergic, intrinsic, extrinsic and dust asthma, particularly chronic or inveterate asthma (e.g. late asthma and airways hyper-responsiveness); bronchitis; acute, allergic, atrophic rhinitis and chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous and pseudomembranous rhinitis and scrofulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) and vasomotor rhinitis; sarcoidosis, farmer's lung and related diseases, fibroid lung and idiopathic interstitial pneumonia;

101365

-11-

- (2) **bone and joints** - rheumatoid arthritis, seronegative spondyloarthropathies (including ankylosing spondylitis, psoriatic arthritis and Reiter's disease), Behcet's disease, Sjogren's syndrome and systemic sclerosis;
- (3) **skin** - psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatides, seborrhoetic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia areata and vernal conjunctivitis;
- (4) **gastrointestinal tract** - Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, indeterminate colitis, microscopic colitis, inflammatory bowel disease, irritable bowel syndrome, non-inflammatory diarrhea, food-related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema;
- (5) **central and peripheral nervous system** - Neurodegenerative diseases and dementia disorders, e.g. Alzheimer's disease, amyotrophic lateral sclerosis and other motor neuron diseases, Creutzfeldt-Jacob's disease and other prion diseases, HIV encephalopathy (AIDS dementia complex), Huntington's disease, frontotemporal dementia, Lewy body dementia and vascular dementia; polyneuropathies, e.g. Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, plexopathies; CNS demyelination, e.g. multiple sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and subacute sclerosing panencephalitis; neuromuscular disorders, e.g. myasthenia gravis and Lambert-Eaton syndrome; spinal disorders, e.g. tropical spastic paraparesis, and stiff-man syndrome; paraneoplastic syndromes, e.g. cerebellar degeneration and encephalomyelitis; CNS trauma; migraine; and stroke.
- (6) **other tissues and systemic disease** - atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus, systemic lupus, erythematosus, Hashimoto's thyroiditis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, lepromatous leprosy, and idiopathic thrombocytopenia purpura; post-operative adhesions, and sepsis.

101365

-12-

- (7) **allograft rejection** - acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea; and chronic graft versus host disease;
- 5 (8) **cancers** - especially non-small cell lung cancer (NSCLC), malignant melanoma, prostate cancer and squamous sarcoma, and tumour metastasis, non melanoma skin cancer and chemoprevention metastases;
- (9) **diseases** - in which angiogenesis is associated with raised CXCR2 chemokine levels (e.g. NSCLC, diabetic retinopathy);
- (10) **cystic fibrosis**;
- 10 (11) **burn wounds & chronic skin ulcers**;
- (12) **reproductive diseases** - for example disorders of ovulation, menstruation and implantation, pre-term labour, endometriosis;
- (13) **re-perfusion injury** - in the heart, brain, peripheral limbs and other organs, inhibition of atherosclerosis.

15 Thus, the present invention provides a compound of formula (1), or a pharmaceutically-acceptable salt, solvate or an *in vivo* hydrolysable ester thereof, as hereinbefore defined for use in therapy.

Preferably the compounds of the invention are used to treat diseases in which the chemokine receptor belongs to the CXC-chemokine receptor subfamily, more preferably the
20 target chemokine receptor is the CXCR2 receptor.

Particular conditions which can be treated with the compounds of the invention are cancer, diseases in which angiogenesis is associated with raised CXCR2 chemokine levels, and inflammatory diseases such as asthma, allergic rhinitis, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis.

25 As a further aspect of the present invention, certain compounds of formula (1) may have utility as antagonists of the CX3CR1 receptor. Such compounds are expected to be particularly useful in the treatment of disorders within the central and peripheral nervous system and other conditions characterized by an activation of microglia and/or infiltration of leukocytes (e.g. stroke/ischemia and head trauma).

30 In a further aspect, the present invention provides a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined for use as a medicament.

101365

-13-

In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined for use as a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

5 In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined for use as a medicament for the treatment of asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis.

10 In a further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.

15 In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined in the manufacture of a medicament for the treatment of asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

25 The invention still further provides a method of treating a chemokine mediated disease wherein the chemokine binds to a chemokine (especially CXCR2) receptor, which comprises administering to a patient a therapeutically effective amount of a compound of formula, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester, as hereinbefore defined.

30 The invention also provides a method of treating an inflammatory disease, especially asthma, allergic rhinitis, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis, in a patient suffering from, or at risk of, said

21. JAN. 2004 16:06

GLOBAL IP PATENTS

NO. 4832 P. 17

101365

-14-

disease, which comprises administering to the patient a therapeutically effective amount of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined.

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.

The compounds of formula (1) and pharmaceutically acceptable salts, solvates or *in vivo* hydrolysable esters thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which formula (1) compound/salt/solvate/ester (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.

The present invention also provides a pharmaceutical composition comprising a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, as hereinbefore defined, with a pharmaceutically acceptable adjuvant, diluent or carrier. The pharmaceutical compositions may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally. Preferably the compounds of the invention are administered orally.

In addition to their use as therapeutic medicines, the compounds of formula (1) and their pharmaceutically acceptable salts, solvate or *in vivo* hydrolysable esters are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effect of chemokine modulation activity in laboratory

101365

-15-

animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

The invention further relates to combination therapies wherein a compound of formula (1) or a pharmaceutically acceptable salts, solvate or *in vivo* hydrolysable ester thereof, or a pharmaceutical composition or formulation comprising a compound of formula (1) is administered concurrently or sequentially with therapy and/or an agent for the treatment of any one of asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis or osteoporosis.

In particular, for the treatment of the inflammatory diseases rheumatoid arthritis, psoriasis, inflammatory bowel disease, irritable bowel syndrome, COPD, asthma and allergic rhinitis the compounds of the invention may be combined with agents such as TNF- α inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and D.sub2.E.sub7.) and TNF receptor immunoglobulin molecules (such as Enbrel.reg.), non-selective COX-1 / COX-2 inhibitors (such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin), COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib) low dose methotrexate, lefunomide; ciclosonide; hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold. For inflammatory bowel disease and irritable bowel disorder further convenient agents include sulphasalazine and 5-ASAs, topical and systemic steroids, immunomodulators and immunosuppressants, antibiotics, probiotics and anti-integrins.

The present invention still further relates to the combination of a compound of the invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted 2-cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-886, and BAY x 1005.

The present invention still further relates to the combination of a compound of the invention together with a receptor antagonist for leukotrienes LTB.sub4., LTC.sub4., LTD.sub4., and LTE.sub4. selected from the group consisting of the phenothiazin-3-ones

101365

-16-

such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

5 The present invention still further relates to the combination of a compound of the invention together with a PDE4 inhibitor including inhibitors of the isoform PDE4D.

The present invention still further relates to the combination of a compound of the invention together with a antihistaminic H_{sub1}. receptor antagonists such as cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine.

10 The present invention still further relates to the combination of a compound of the invention together with a gastroprotective H_{sub2}. receptor antagonist.

The present invention still further relates to the combination of a compound of the invention together with an α .sub1.- and α .sub2.-adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, 15 pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride.

The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents such as ipratropium bromide; tiotropium bromide; oxitropium bromide; pirzepine; and telenzepine.

20 The present invention still further relates to the combination of a compound of the invention together with a β .sub1.- to β .sub4.-adrenoceptor agonists such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscarinic receptor (M1, M2, and 25 M3) antagonist.

The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-I) mimetic.

The present invention still further relates to the combination of a compound of the invention together with an inhaled glucocorticoid with reduced systemic side effects, such as 30 prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate.

The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins,

101365

-17-

the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-12.

The present invention still further relates to the combination of a compound of the
5 invention together with other modulators of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX₃CR1 for the C-X₃-C family.

The present invention still further relates to the combination of a compound of the
10 invention together with antiviral agents such as Viracept, AZT, aciclovir and famciclovir, and antiseptis compounds such as Valant.

The present invention still further relates to the combination of a compound of the
invention together with cardiovascular agents such as calcium channel blockers, lipid
lowering agents such as statins, fibrates, beta-blockers, Ace inhibitors, Angiotensin-2 receptor
15 antagonists and platelet aggregation inhibitors.

The present invention still further relates to the combination of a compound of the
invention together with CNS agents such as antidepressants (such as sertraline), anti-
Parkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as
selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake
20 inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of
neuronal nitric oxide synthase), and anti-Alzheimer's drugs such as donepezil, tacrine, COX-2
inhibitors, propentofylline or metryfonate.

The present invention still further relates to the combination of a compound of the
invention together with (i) tryptase inhibitors; (ii) platelet activating factor (PAF) antagonists;
25 (iii) interleukin converting enzyme (ICE) inhibitors; (iv) IMPDH inhibitors; (v) adhesion
molecule inhibitors including VLA-4 antagonists; (vi) cathepsins; (vii) MAP kinase
inhibitors; (viii) glucose-6 phosphate dehydrogenase inhibitors; (ix) kinin-B.sub1. - and
B.sub2. -receptor antagonists; (x) anti-gout agents, e.g., colchicine; (xi) xanthine oxidase
inhibitors, e.g., allopurinol; (xii) uricosuric agents, e.g., probenecid, sulfinpyrazone, and
30 benzbromarone; (xiii) growth hormone secretagogues; (xiv) transforming growth factor
(TGF β); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factor, e.g., basic
fibroblast growth factor (bFGF); (xvii) granulocyte macrophage colony stimulating factor
(GM-CSF); (xviii) capsaicin cream; (xix) Tachykinin NK.sub1. and NK.sub3. receptor

101365

-18-

antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; (xx) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892; (xxi) TNF α converting enzyme inhibitors (TACE); (xxii) induced nitric oxide synthase inhibitors (iNOS) or (xxiii) chemoattractant receptor-homologous molecule expressed on TH2 cells, 5 (CRTH2 antagonists).

The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax and immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate;.

10 The compounds of the invention may also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, 15 apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, analgesics and intraarticular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc and P2X7 receptor antagonists.

The compounds of the invention can also be used in combination with existing 20 therapeutic agents for the treatment of cancer. Suitable agents to be used in combination include:

(i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for 25 example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine and paclitaxel (Taxol®); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and 30 vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example fulvestrant),

101365

-19-

- antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuporelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as
- 5 finasteride;
- (iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erb2 antibody
- 10 trastuzumab [HerceptinTM] and the anti-erb1 antibody cetuximab [C225]) , farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-
- 15 bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;
- (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial
- 20 growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [AvastinTM], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin);
- 25 (vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO00/40529, WO 00/41669, WO01/92224, WO02/04434 and WO02/08213;
- (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;
- 30 (viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial

101365

-20-

nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

- (ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-Idiotypic antibodies.

Pharmacological Data

10 Ligand Binding Assay

- [¹²⁵I]IL-8 (human, recombinant) was purchased from Amersham, U.K. with a specific activity of 2,000Ci/mmol. All other chemicals were of analytical grade. High levels of hrCXCR2 were expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No. 85120602) (Lee *et al.* (1992) *J. Biol. Chem.* 267 pp16283-16291). hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA. The DNA was cloned into PCRScript (Stratagene) and clones were identified using DNA. The coding sequence was sub-cloned into the eukaryotic expression vector RcCMV (Invitrogen). Plasmid DNA was prepared using Quiagen Megaprep 2500 and transfected into HEK 293 cells using Lipofectamine reagent (Gibco BRL). Cells of the highest expressing clone were harvested in phosphate-buffered saline containing 0.2%(w/v) ethylenediaminetetraacetic acid (EDTA) and centrifuged (200g, 5min.). The cell pellet was resuspended in ice cold homogenisation buffer [10mM HEPES (pH 7.4), 1mM dithiothreitol, 1mM EDTA and a panel of protease inhibitors (1mM phenyl methyl sulphonyl fluoride, 2µg/ml soybean trypsin inhibitor, 3mM benzamidine, 0.5µg/ml leupeptin and 100µg/ml bacitracin)] and the cells left to swell for 10 minutes. The cell preparation was disrupted using a hand held glass mortar/PTFE pestle homogeniser and cell membranes harvested by centrifugation (45 minutes, 100,000g, 4°C). The membrane preparation was stored at -70°C in homogenisation buffer supplemented with Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH₂PO₄, 0.1%(w/v) gelatin and 10%(v/v) glycerol.

- All assays were performed in a 96-well MultiScreen 0.45µm filtration plates (Millipore, U.K.). Each assay contained ~50pM [¹²⁵I]IL-8 and membranes (equivalent to ~200,000 cells) in assay buffer [Tyrode's salt solution supplemented with 10mM HEPES (pH 7.4), 1.8mM CaCl₂, 1mM MgCl₂, 0.125mg/ml bacitracin and 0.1%(w/v) gelatin]. In addition, a compound of formula (I) according to the Examples was pre-dissolved in DMSO and added

101365

-21-

to reach a final concentration of 1%(v/v) DMSO. The assay was initiated with the addition of membranes and after 1.5 hours at room temperature the membranes were harvested by filtration using a Millipore MultiScreen vacuum manifold and washed twice with assay buffer (without bacitracin). The backing plate was removed from the MultiScreen plate assembly, 5 the filters dried at room temperature, punched out and then counted on a Cobra gamma-counter.

The compounds of formula (I) according to the Examples 1 – 2 were found to have IC_{50} values of greater than ($>$) 5.0.

Intracellular Calcium Mobilisation Assay

10 Human neutrophils were prepared from EDTA-treated peripheral blood, as previously described (Baly *et al.* (1997) *Methods in Enzymology* 287 pp70-72), in storage buffer [Tyrode's salt solution (137mM NaCl, 2.7mM KCl, 0.4mM NaH_2PO_4) supplemented with 5.7mM glucose and 10mM HEPES (pH 7.4)].

The chemokine GRO δ (human, recombinant) was purchased from R&D Systems 15 (Abingdon, U.K.). All other chemicals were of analytical grade. Changes in intracellular free calcium were measured fluorometrically by loading neutrophils with the calcium sensitive fluorescent dye, fluo-3, as described previously (Merritt *et al.* (1990) *Biochem. J.* 269, pp513-519). Cells were loaded for 1 hour at 37°C in loading buffer (storage buffer with 0.1%(w/v) gelatin) containing 5 μ M fluo-3 AM ester, washed with loading buffer and then resuspended in 20 Tyrode's salt solution supplemented with 5.7mM glucose, 0.1%(w/v) bovine serum albumin (BSA), 1.8mM $CaCl_2$ and 1mM $MgCl_2$. The cells were pipetted into black walled, clear bottom, 96 well micro plates (Costar, Boston, U.S.A.) and centrifuged (200g, 5 minutes, room temperature).

A compound of formula (I) according to the Examples was pre-dissolved in 25 DMSO and added to a final concentration of 0.1%(v/v) DMSO. Assays were initiated by the addition of an A_{50} concentration of GRO δ and the transient increase in fluo-3 fluorescence (δ_{Ex} = 490nm and δ_{Em} = 520nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).

The compounds of formula (I) according to the Examples were tested and found to 30 be antagonists of the CXCR2 receptor in human neutrophils.

The invention will now be illustrated by the following non-limiting Examples in which, unless stated otherwise:

101365

-22-


- (i) when given Nuclear Magnetic Resonance (NMR) spectra were measured on a Varian Unity Inova 300 or 400 MHz spectrometer. ¹H NMR data is quoted in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard.
- 5 (ii) Mass Spectrometry (MS) spectra were measured on a Finnigan Mat SSQ7000 or Micromass Platform spectrometer.
- (iii) the title and sub-titled compounds of the Examples and methods were named using the ACD/Name program (version 4.55) from Advanced Chemical Development Inc, Canada.
- 10 (iv) Normal phase column chromatography and normal phase HPLC was conducted using a silica column. Reverse phase High Pressure Liquid Chromatography (HPLC) purification was performed using either a Waters Micromass LCZ with a Waters 600 pump controller, Waters 2487 detector and Gilson FC024 fraction collector or a Waters Delta Prep 4000 or a Gilson Auto Purification System, using
- 15 a Symmetry, NovaPak or Ex-Terra reverse phase silica column.
- (v) The following abbreviations are used:
- | | |
|-------------------|-------------------------------|
| AcOH | acetic acid |
| CHCl ₃ | chloroform |
| DCM | dichloromethane |
| 20 DMF | <i>N,N</i> -dimethylformamide |
| DMSO | dimethylsulfoxide |
| Et ₂ O | diethyl ether |
| EtOAc | ethyl acetate |
| MgSO ₄ | magnesium sulfate |
| 25 NMP | 1-methylpyrrolidin-2-one |
| THF | tetrahydrofuran |
| H ₂ O | water |
- 30

101365

-23-

Example 1

N-[4-[[[(2,3-difluorophenyl)methyl]thio]-6-[[[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-methanesulfonamide



5 A mixture of methane sulphonamide (0.17 g), tris(dibenzylideneacetone)dipalladium (0) (13 mg), (9,9-dimethyl-9*H*-xanthene-4,5-diyl)bis[diphenyl-phosphine (8 mg) and cesium carbonate were stirred under a nitrogen atmosphere for 5 minutes. A solution of 2-[[4-chloro-6-[[[(2,3-difluorophenyl)methyl]thio]-1,3,5-triazin-2-yl]amino]-(2*R*)-1-propanol (0.5 g) in anhydrous 1,4-dioxane (5 ml) was added to the above mixture and the reaction was heated to
10 reflux in a pre-heated heat on block for 25 minutes. The reaction mixture was allowed to cool to ambient temperature, diluted with 1*N* aqueous hydrochloric acid solution and extracted with ethyl acetate (x3). The combined organic layers were dried with magnesium sulfate, filtered and evaporated. The residue was purified by column chromatography on silica using a 99:1 to 98:2 mixture of methylene chloride and methanol as eluent. The resulting solid was
15 further purified by reverse phase HPLC using a 95:5 to 5:95 mixture of 0.2% aqueous ammonium acetate solution and acetonitrile as eluent to give the title compound as a white solid (0.3 g).

NMR Spectrum: (CD₃OD) 1.21 (m, 3H), 3.33 (m, 3H), 3.58 (m, 2H), 4.19 (m, 1H), 4.56 (m, 2H), 7.16 (m, 2H), 7.38 (m, 1H);

20 Mass Spectrum: M+H⁺ 406;

Elemental Analysis: Found C, 40.05; H, 4.80; N, 16.48; C₁₄H₁₇F₂N₃O₃S₂·1H₂O requires C, 39.71; H, 4.52; N, 16.54%.

The 2-[[4-chloro-6-[[[(2,3-difluorophenyl)methyl]thio]-1,3,5-triazin-2-yl]amino]-(2*R*)-1-propanol used as a starting material was prepared as follows :-

25

i) (2,3-difluorophenyl)methanethiol

Thiourea (6.7 g) was added to a stirred solution of 2,3-difluorobenzylbromide (18.3 g), in ethanol (300 ml). The reaction mixture was heated at reflux for 2.5 hours and then evaporated, treated with 2*N* sodium hydroxide solution (440 ml) and heated at reflux for a

101365

-24-

further 4 hours and left stirring at ambient temperature overnight. The resulting mixture was ice-cooled, acidified to pH 6 using concentrated aqueous hydrochloric acid solution and then extracted with diethyl ether. The organic layer was separated, washed with water, dried over anhydrous magnesium sulphate, filtered and evaporated to give (2,3-difluorophenyl)methanethiol (8.0 g). NMR Spectrum: (CDCl₃) 1.90 (t, 1H), 3.78 (d, 2H), 7.06 (m, 3H).

ii) 2-[[4-chloro-6-[(2,3-difluorophenyl)methyl]thio]-1,3,5-triazin-2-yl]amino]-(2R)-1-propanol


To an ice-bath cooled solution of cyanuric chloride (3.0 g) and diisopropylethylamine (3.1 ml) in anhydrous tetrahydrofuran (100 ml) was added a solution of (2,3-difluorophenyl)methanethiol (2.6 g) dropwise over 30 minutes. The reaction mixture was stirred at 0°C under a nitrogen atmosphere for 40 minutes. Further diisopropylethylamine (3.1 ml) was added, followed by a solution of R-(D)-alaninol (1.2 g) in anhydrous tetrahydrofuran (20 ml) dropwise over 5 minutes. The resulting reaction mixture was stirred at 0°C under a nitrogen atmosphere for 55 minutes. The mixture was diluted with brine and extracted with ethyl acetate (x2). The combined organic layers were dried with magnesium sulfate, filtered and evaporated. The residue was purified by column chromatography on silica using a 90:10 to 70:30 to 60:40 mixture of iso-hexane and ethylacetate as eluent to give 2-[[4-chloro-6-[(2,3-difluorophenyl)methyl]thio]-1,3,5-triazin-2-yl]amino]-(2R)-1-propanol as a white solid (5.1 g).

NMR Spectrum: (DMSO) 1.16 (m, 3H), 3.37 (m, 2H), 4.02 (m, 1H), 4.43 (m, 2H), 4.76 (m, 1H), 7.16 (m, 1H), 7.38 (m, 2H), 8.49 (t, 1H);

Mass Spectrum: M+H⁺ 347/349

Example 2

N-[4-[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethyl]amino]-1,3,5-triazin-2-yl]-1-azetidinesulfonamide



101365

-25-

Prepared using the same procedure as for the title compound in example 1; from 2-[[4-chloro-6-[[[(2,3-difluorophenyl)methyl]thio]-1,3,5-triazin-2-yl]amino]-(2*R*)-1-propanol (0.5 g) and azetidine-1-sulfonamide (0.25g) to give the title compound as a white solid (120 mg).

NMR Spectrum: (CD₃OD) 1.18 (m, 3H), 2.17 (quintet, 2H), 3.55 (m, 2H), 4.06 (t, 4H), 4.16
5 (m, 1H), 4.43 (m, 2H), 7.12 (m, 2H), 7.37 (m, 1H);

Mass Spectrum: M+H⁺ 447;

Elemental Analysis: Found C, 42.52; H, 4.86; N, 17.68; C₁₆H₂₀F₂N₆O₃S₂·0.3H₂O·0.3AcOH
requires C, 42.43; H, 4.68; N, 17.88%.


10

101365

-26-

CLAIMS

1. A compound of formula (1), or a pharmaceutically acceptable salt, solvate or *in vivo*
 5 hydrolysable ester thereof:



- wherein Y is selected from a bond, -S-, -O-, -NR⁵-, -CF₂-CH₂-, -CF₂CF₂-, -CONR⁵-,
 10 phenyl or heteroaryl.
 wherein R¹ is a group selected from C₃-₇carbocyclyl, C₁-₈alkyl, C₂-₆alkenyl and C₂-₆alkynyl;
 wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected
 from fluoro, nitrile, -OR⁴, -NR⁵R⁶, -CONR⁵R⁶, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -SO₂R¹⁰,
 -SO₂NR⁵R⁶, -NR⁸SO₂R⁹, phenyl or heteroaryl; wherein phenyl and heteroaryl are optionally
 15 substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, -OR⁴, -
 NR⁵R⁶, -CONR⁵R⁶, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -SO₂R¹⁰, -SO₂NR⁵R⁶, -NR⁸SO₂R⁹,
 C₁-₆alkyl and trifluoromethyl;
 wherein R² is C₃-₇carbocyclyl, optionally substituted by 1, 2 or 3 substituents independently
 selected from:
 20 (a) fluoro, -OR⁴, -NR⁵R⁶, -CONR⁵R⁶, -COOR⁷, -NR⁸COR⁹, -SR¹⁰, -SO₂R¹⁰, -SO₂NR⁵R⁶,
 -NR⁸SO₂R⁹;
 (b) a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected from O, S, -NR⁸
 and whereby the ring is optionally substituted by C₁-₃alkyl or fluoro; or
 (c) phenyl or heteroaryl, each of which is optionally substituted by 1, 2 or 3 substituents
 25 independently selected from halo, cyano, nitro, -OR⁴, -NR⁵R⁶, -CONR⁵R⁶, -NR⁸COR⁹, -
 SO₂NR⁵R⁶, -NR⁸SO₂R⁹, C₁-₆alkyl and trifluoromethyl;
 or R² is a group selected from C₁-₈alkyl, C₂-₆alkenyl or C₂-₆alkynyl wherein the group is
 substituted by 1, 2 or 3 substituents independently selected from hydroxy, amino, C₁-₆alkoxy,
 C₁-₆alkylamino, di(C₁-₆alkyl)amino, N-(C₁-₆alkyl)-N-(phenyl)amino, N-C₁-₆alkylcarbamoyl,

101365

-27-

- N,N*-di(C_{1-6} alkyl)carbamoyl, *N*-(C_{1-6} alkyl)-*N*-(phenyl)carbamoyl, carboxy, phenoxycarbonyl, $-NR^3COR^9$, $-SO_2R^{10}$, $-SO_2NR^5R^6$ and $-NR^8SO_2R^9$; wherein R^3 is hydrogen or independently R^2 ;
- R^4 is hydrogen or a group selected from C_{1-6} alkyl and phenyl, wherein the group is optionally substituted by 1 or 2 substituents independently selected from halo, phenyl, $-OR^{11}$ and $-NR^{12}R^{13}$;
- R^5 and R^6 are independently hydrogen or a group selected from C_{1-6} alkyl and phenyl wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl, $-OR^{14}$, $-NR^{15}R^{16}$, $-COOR^{14}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2R^{10}$, $-SONR^{15}R^{16}$ and $-NR^{15}SO_2R^{16}$;
- or R^5 and R^6 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring system optionally containing a further heteroatom selected from oxygen and nitrogen atoms, which ring is optionally substituted by 1, 2 or 3 substituents independently selected from phenyl, $-OR^{14}$, $-COOR^{14}$, $-NR^{15}R^{16}$, $-CONR^{15}R^{16}$, $-NR^{15}COR^{16}$, $-SO_2R^{10}$, $-SONR^{15}R^{16}$, $-NR^{15}SO_2R^{16}$ or C_{1-6} alkyl (optionally substituted by 1 or 2 substituents independently selected from halo, $-NR^{15}R^{16}$ and $-OR^{17}$ groups);
- R^{10} is hydrogen or a group selected from C_{1-6} alkyl or phenyl, wherein the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, phenyl, $-OR^{17}$ and $-NR^{15}R^{16}$; and each of R^7 , R^8 , R^9 , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} is independently hydrogen, C_{1-6} alkyl or phenyl;
- R^8 is trifluoromethyl, $-NR^5R^6$, phenyl, naphthyl, monocyclic or bicyclic heteroaryl wherein a heteroring may be partially or fully saturated and one or more ring carbon atoms may form a carbonyl group, and wherein each phenyl or heteroaryl group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, C_{1-6} alkyl or trifluoromethyl;;
- or R^7 is a group selected from C_{3-7} carbocyclyl, C_{1-8} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl whereby the group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, $-OR^4$, $-NR^5R^6$, $-CONR^5R^6$, $-COR^7$, $-COOR^7$, $-NR^8COR^9$, $-SR^{10}$, $-SO_2R^{10}$, $-SO_2NR^5R^6$, $-NR^8SO_2R^9$, phenyl or heteroaryl; and wherein each phenyl or heteroaryl group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, cyano, nitro, $-OR^4$, -

101365

-28-

NR^5R^6 , $-\text{CONR}^5\text{R}^6$, $-\text{COR}^7$, $-\text{COOR}^7$, $-\text{NR}^8\text{COR}^9$, $-\text{SR}^{10}$, $-\text{SO}_2\text{R}^{10}$, $-\text{SO}_2\text{NR}^5\text{R}^6$,
 $-\text{NR}^8\text{SO}_2\text{R}^9$, C_{1-6} alkyl or trifluoromethyl;

2. A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable
 5 ester thereof according to claim 1 wherein R^2 is C_{1-6} alkyl optionally substituted by 1 or 2
 hydroxy substituents.
3. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester
 thereof according to claim 1 wherein R^1 is benzyl optionally substituted by 1, 2 or 3
 10 substituents independently selected from fluoro, chloro, bromo, methoxy, methyl and
 trifluoromethyl.
4. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester
 thereof wherein R^3 is hydrogen.
- 15 5. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester
 thereof wherein Y is selected from a bond, -S-, and $-\text{CF}_2-\text{CH}_2-$.
6. A compound, pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester
 20 thereof wherein R^x is methyl, 1-methylimidazolyl, 1,2-dimethylimidazolyl, *N,N*-
 dimethylamino, azetidiny, pyrrolidinyl, morpholinyl and piperidinyl.
7. A compound selected from the group consisting of:
 N -[4-[(2,3-difluorophenyl)methyl]thio]-6-[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-
 25 triazin-2-yl]-methanesulfonamide; and
 N -[4-[(2,3-difluorophenyl)methyl]thio]-6-[(1*R*)-2-hydroxy-1-methylethyl]amino]-1,3,5-
 triazin-2-yl]-1-azetidinesulfonamide
 or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof.
- 30 8. A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable
 ester thereof according to any one of claims 1 to 7 for use as a medicament.


101365

-29-

9. A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to any one of claims 1 to 7 for use as a medicament for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis..
- 5 10. A compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to any one of claims 1-7, for use as a medicament for the treatment of cancer.
- 10 11. The use of a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial.
- 15 12. The use of a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of asthma, allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, or psoriasis.
- 20 13. The use of a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, according to any one of claims 1 to 7 in the manufacture of a medicament for the treatment of cancer.
- 25 14. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof according to any one of claims 1 to 7 and a pharmaceutically-acceptable diluent or carrier.
15. A process for the preparation of a compound according to claim 1 or a
30 pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, which comprises the steps of:
treating a compound of formula (2):

101365

-30-



wherein Y, R¹, R² and R³ are as defined in formula (1) with a sulfonamide of formula

- 5 R^xSO₂NH₂ where R^x is as defined in formula (1);
 and optionally thereafter, one or more of steps (i), (ii), (iii), (iv), or (v) in any order:
 i) removing any protecting groups;
 ii) converting the compound of formula (1) into a further compound of formula (1)
 iii) forming a salt
 10 iv) forming a prodrug
 v) forming an *in vivo* hydrolysable ester.
16. A combination therapy which comprises administering a compound of formula (1) or
 a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, or a
 15 pharmaceutical composition or formulation comprising a compound of formula (1),
 concurrently or sequentially with other therapy and/or another pharmaceutical agent.
17. A combination therapy as claimed in claim 16 for the treatment of asthma, allergic
 rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis,
 20 osteoporosis, rheumatoid arthritis, or psoriasis.
18. A combination therapy as claimed in claim 16 for the treatment of cancer.
19. A pharmaceutical composition which comprises a compound of formula (1) or a
 25 pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof, in conjunction
 with another pharmaceutical agent.
20. A pharmaceutical composition as claimed in claim 19 for the treatment of asthma,
 allergic rhinitis, COPD, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis,
 30 osteoporosis, rheumatoid arthritis, or psoriasis.

101365

-31-


21. A pharmaceutical composition as claimed in claim 19 for the treatment of cancer.

101365

-32-

ABSTRACTTITLE: COMPOUNDS

- 5 A compound of formula (I), or a pharmaceutically acceptable salt, solvate or *in vivo* hydrolysable ester thereof:



- 10 and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders

From the INTERNATIONAL BUREAU

PCTNOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

ASTRAZENECA
Global Intellectual Property
S-SE-151 85 Sodertalje
SUÈDE

Date of mailing (<i>day/month/year</i>) 11 April 2005 (11.04.2005)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 101365-1 WO	
International application No. PCT/GB05/000180	International filing date (<i>day/month/year</i>) 19 January 2005 (19.01.2005)
International publication date (<i>day/month/year</i>)	Priority date (<i>day/month/year</i>) 21 January 2004 (21.01.2004)
Applicant ASTRAZENECA AB et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable)* The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable)* An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
21 January 2004 (21.01.2004)	0401269.6	GB	02 March 2005 (02.03.2005)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Lindner Nora

Facsimile No. +41 22 740 14 35

Facsimile No. +41 22 338 89 65
Telephone No. +41 22 338 9720

From the INTERNATIONAL BUREAU

PCTNOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

ASTRAZENECA
Global Intellectual Property
S-SE-151 85 Sodertalje
SUÈDE

Date of mailing (day/month/year) 11 April 2005 (11.04.2005)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 101365-1 WO	
International application No. PCT/GB05/000180	
International publication date (day/month/year)	
	International filing date (day/month/year) 19 January 2005 (19.01.2005)
	Priority date (day/month/year) 21 January 2004 (21.01.2004)
Applicant ASTRAZENECA AB et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable)* The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable)* An asterisk (*) appearing next to a date of receipt, in the right-hand column, denotes a priority document **submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b)** (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as the priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

<u>Priority date</u>	<u>Priority application No.</u>	<u>Country or regional Office or PCT receiving Office</u>	<u>Date of receipt of priority document</u>
21 January 2004 (21.01.2004)	0401269.6	GB	02 March 2005 (02.03.2005)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. +41 22 740 14 35

Authorized officer

Lindner Nora

Facsimile No. +41 22 338 89 65
Telephone No. +41 22 338 9720

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.